Pomegranate compound with anti-aging effects passes human trial

A recent clinical trial involving two EPFL entities—spin-off Amazentis and the Laboratory of Integrative Systems Physiology (LISP) – showed that urolithin A, a compound derived from biomolecules found in fruits such as pomegranates, could slow down this process by improving the functioning of mitochondria—the cells’ powerhouses. A joint paper presenting the results of the trial, published today in Nature Metabolism, also demonstrates that ingesting the compound poses no risk to human health. The team then assessed the efficacy of UA by looking at cellular and mitochondrial health biomarkers in the participants’ blood and muscle tissue.

Source: medicalxpress.com